Cephalalgia

Papers
(The TQCC of Cephalalgia is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study: Methods and multi-country baseline findings for diagnosis rates and care109
Harassment in the headache field: a global web-based cross-sectional survey87
A reply, drug-induced reversible cerebral vasoconstriction syndrome: Lessons from the real world81
High perceived isolation and reduced social support affect headache impact levels in migraine after the Covid-19 outbreak: A cross sectional survey on chronic and episodic patients80
Efficacy and tolerability of combination treatment of topiramate and greater occipital nerve block versus topiramate monotherapy for the preventive treatment of chronic migraine: A randomized controll68
International Classification of Headache Disorders-4 – Work in Progress 162
Evidence-based guidelines for the pharmacological treatment of migraine59
Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials59
Depression screening in migraine - A double-edged sword54
Population-based prevalence of cranial autonomic symptoms in migraine and proposed diagnostic appendix criteria54
Assessing migraine therapeutics51
Genome-wide DNA methylation analysis in an antimigraine-treated preclinical model of cortical spreading depolarization49
Comment on “What predicts citation counts and translational impact in headache research? A machine learning analysis”44
Call for papers42
Corrigendum to: Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex40
Systemic lupus erythematosus mimicking retinal migraine: a case report39
Diagnosis of idiopathic intracranial hypertension - the importance of excluding secondary causes: A systematic review39
Pain sensitivities predict prophylactic treatment outcomes of flunarizine in chronic migraine patients: A prospective study36
Triptan non-response in a London tertiary headache centre: What can we learn? A retrospective study35
Effect of Altmetric score on manuscript citations: A randomized-controlled trial35
CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis32
History of maternal migraine and its association with preeclampsia: A case–control study in a low-resource setting in Sudan, Africa31
An altered reward system characterizes chronic migraine with medication overuse headache30
Guidelines of the International Headache Society for controlled trials of pharmacological preventive treatment for persistent post-traumatic headache attributed to mild traumatic brain injury30
Painful nervus intermedius neuropathy attributed to Bell's palsy: The need for independent diagnostic criteria28
Paroxysmal hemicrania and hemicrania continua: Review on pathophysiology, clinical features and treatment28
The effects of certain TRP channels and voltage-gated KCNQ/Kv7 channel opener retigabine on calcitonin gene-related peptide release in the trigeminovascular system28
Childhood and adolescent headache: A problem not to be ignored in the era of new therapies28
COVID-19 vaccination-triggered cluster headache episodes with frequent attacks27
Galcanezumab modulates Capsaicin-induced C-fiber reactivity27
Effect of COVID vaccination on monthly migraine days: a longitudinal cohort study27
Immunogenicity of erenumab: A pooled analysis of six placebo-controlled trials with long-term extensions27
Case reports: Could sexual dysfunction in women with migraine be a side effect of CGRP inhibition?27
Physical impairment during and between migraine attacks: A daily diary study of patients with chronic migraine27
Migraine and risk of atrial fibrillation: A 9-year follow-up based on the Trøndelag Health Study27
Long-term open-label and real-world studies of lasmiditan, ubrogepant, and rimegepant for the acute treatment of migraine attacks26
Guidelines of the International Headache Society for Clinic-Based Headache Registries, 1st edition26
Author response to ‘Clarification on the incidence and sex-specificity of sexual dysfunction as an adverse event of CGRP-targeting medications’25
Comorbidity or combination – more evidence for cluster-migraine?25
The midfacial segment pain: little known disorder in need of scientific evaluation24
Looking at Cephalalgia from the inside23
Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: Updated analysis in VigiBase®23
Crossing the Rubicon? The future impact of artificial intelligence on headache medicine23
Sex differences in photophobic behaviors following cortical spreading depression in rats23
The non-decussating and decussating trigeminothalamic tracts in humans: A combination of connectome-based tractography and histological validation23
Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients22
A placebo-controlled, randomized, single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of rimegepant in healthy participants22
Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks22
Sensitivity of the SNNOOP10 list in the high-risk secondary headache detection21
Guidelines Update: Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition – An experience-based update21
What is the evolutionary disadvantage of migraine?21
The “index vein” as a sign for migraine aura in the emergency setting20
Muscae volitantes: A 19th-century precursor of visual snow syndrome?20
Burden of headache in a HIV-positive population of sub-Saharan Africa19
Thanks to Reviewers19
Abstracts from the International Headache Congress 14–17 September 202319
Migraine-attributed burden, impact and disability, and migraine-impacted quality of life: Expert consensus on definitions from a Delphi process18
Worldwide availability of medications for migraine and tension-type headache: A survey of the International Headache Society18
Alopecia as an emerging adverse event to CGRP monoclonal antibodies: Cases Series, evaluation of FAERS, and literature review18
Abnormal heart rate variability and its application in predicting treatment efficacy in patients with chronic migraine: An exploratory study18
Involvement of adenosine signaling pathway in migraine pathophysiology: A systematic review of clinical studies18
The impact of eating disorders on idiopathic intracranial hypertension17
Psychophysical testing in chronic migraine and chronic tension type headache: An observational study17
Are we closer to achieving precision medicine for migraine treatment? A narrative review17
Advancing understanding of migraine pathophysiology and therapy by consideration of patient sex17
Erratum17
Poor social support and loneliness in chronic headache: Prevalence and effect modifiers17
Efficacy and safety of monoclonal antibodies targeting CGRP in migraine prevention. GRADE tables elaborated by the ad hoc working group of the International Headache Society16
Efficacy of eptinezumab in non-responders to subcutaneous monoclonal antibodies against CGRP and the CGRP receptor: A retrospective cohort study16
Corneal confocal microscopy identifies corneal nerve fiber loss in patients with migraine16
Letter to the Editor regarding “Effect of Altmetric score on manuscript citations: A randomized-controlled trial”16
Shared genetics and causal relationships between migraine and thyroid function traits16
Exploring the association between familial hemiplegic migraine genes (CACNA1A, ATP1A2 and SCN1A) with migraine and epilepsy: A UK Biobank exome-wide association study16
Stroke due to small-vessel disease and migraine: A case–control study of a young adult with ischemic stroke population16
Neurological and psychiatric comorbidities of migraine: Concepts and future perspectives15
Premonitory symptoms in migraine: A REFORM Study15
BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm15
Two-year, real-world erenumab persistence and quality of life data in 82 pooled patients with abrupt onset, unremitting, treatment refractory headache and a migraine phenotype: New daily persistent he15
Guidelines of the International Headache Society for Controlled Clinical Trials in Cluster Headache15
Corrigendum: No structural brain alterations in new daily persistent headache – a cross sectional VBM/SBM study15
Are the ICHD-3 criteria for headache attributed to idiopathic intracranial hypertension valid? Headache phenotyping and field-testing in newly diagnosed idiopathic intracranial hypertension15
Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients15
Effectiveness of anti-CGRP monoclonal antibodies and onabotulinumtoxinA in menstrually-related migraine: The unmet need of perimenstrual headache days15
Internet and social media's role in migraine education: Headache or not headache?15
Cigarette smoking history (personal and secondary childhood exposure) in non-cluster headache trigeminal autonomic cephalalgias: A clinic based study14
Proposed general diagnostic criteria for secondary headaches14
The long-term effect of work schedule, shift work disorder, insomnia and restless legs syndrome on headache among nurses: A prospective longitudinal cohort study14
Bridging the gaps of headache care for underserved populations: Current status of the headache field in Latin America14
Comment on “Lack of reproducibility of resting-state functional MRI findings in migraine with aura”14
Postprandial fasting related headache during Ramadan in Saudi Arabia: A cross-sectional study14
Board Walk – April 202214
Hypnic Headache – What do we know in 2022?14
Comparison of continuous headache features in youth with migraine, new daily persistent headache, and persistent post-traumatic headache14
New migraine drugs: A critical appraisal of the reason why the majority of migraine patients do not receive an adequate medication14
Electrophysiological findings in migraine may reflect abnormal synaptic plasticity mechanisms: A narrative review13
Headache at the chronic stage of cerebral venous thrombosis13
Children under 6 years with acute headache in Pediatric Emergency Departments. A 2-year retrospective exploratory multicenter Italian study13
“Wearing-off” efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials13
Recurrent Painful Ophthalmoplegic Neuropathy: A case report with atypical features and a review of the literature13
Prevalence and treatment of typical and atypical headaches in patients with Chiari I malformation: A meta-analysis and literature review13
Reply to “Methodological considerations in assessing the impact of CGRP monoclonal antibodies on blood pressure”13
Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study13
Avoidance behaviour modulates but does not condition phonophobia in migraine13
Longitudinal trajectories of posttraumatic headache after pediatric mild traumatic brain injury13
Prevalence of neck pain in migraine: A systematic review and meta-analysis13
Late Breaking Author Index12
Other primary headaches: Distinct clinical features and uncertain pathophysiology12
Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review12
Longitudinal differences in iron deposition in periaqueductal gray matter and anterior cingulate cortex are associated with response to erenumab in migraine12
Mutation screening and association analysis of NOTCH3 p.R544C in patients with migraine with or without aura12
Cephalalgia: a legacy of excellence, a vision for tomorrow12
Timing of headache after COVID-19 vaccines and its association with cerebrovascular events: An analysis of 41,700 VAERS reports12
Orofacial pain for clinicians: A review of constant and attack-like facial pain syndromes12
Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial12
Hypersensitivity to CGRP as a predictive biomarker of migraine prevention with erenumab12
What do people want to know about “Growing Up with Migraine”? Results of a preference survey of people with lived experience to guide future research12
Smooth muscle ATP-sensitive potassium channels mediate migraine-relevant hypersensitivity in mouse models12
Activation of the trigeminal system as a likely target of SARS-CoV-2 may contribute to anosmia in COVID-1912
Oxygen inhalation has no effect on provoked cranial autonomic symptoms using kinetic oscillation stimulation in healthy volunteers12
Persistent headache attributed to past cervicocephalic artery dissection: clinical characteristics and contributors to headache persistence11
Epicranial headaches part 2: Nummular headache and epicrania fugax11
Migraine and the risk of stroke in a middle-aged and elderly population: A prospective cohort study11
Response to letter to the Editor: Assessing migraine therapeutics11
Comment on ‘'Correlation between endometriosis and migraine features: Results from a prospective case-control study'‘11
A need for an expert consensus guideline on performing peripheral nerve blocks in headache patients11
Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study10
Naratriptan is as effective as sumatriptan for the treatment of migraine attacks when used properly. A mini-review10
An evolving machine-learning-based algorithm to early predict response to anti-CGRP monoclonal antibodies in patients with migraine10
Multidisciplinary headache treatment with work-focus in Norway: An observational study10
Headache provocation by nitric oxide in men who have never experienced a headache10
Open label experience of repeated OnabotulinumtoxinA injections towards the sphenopalatine ganglion in patients with chronic cluster headache and chronic migraine10
Pathophysiology of cluster headache: From the trigeminovascular system to the cerebral networks10
How migraine and its associated treatment impact on pregnancy outcomes: Umbrella review with updated systematic review and meta-analysis10
Lack of a direct link between macular cones function and photophobia in interictal migraine10
Personal view: Modelling pain mechanisms of migraine without aura10
The SIH-EBP Score: A grading scale to predict the response to the first epidural blood patch in spontaneous intracranial hypotension10
Treatment experiences and clinical characteristics in migraine and tension-type headache patients before the first visit to a tertiary headache center10
Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study10
Developing an artificial intelligence-based headache diagnostic model and its utility for non-specialists’ diagnostic accuracy10
Recovery and long-term outcome after neurosurgical closure of spinal CSF leaks in patients with spontaneous intracranial hypotension10
Measuring headache day severity using multiple features in daily diary designs10
Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies10
Overuse of analgesics can affect the fertility biomarker Anti-Müllerian Hormone in females. A translational study10
Update in the understanding of new daily persistent headache10
Health care resource utilization and costs associated with diagnosed medication overuse headache and potential acute medication overuse in individuals with migraine10
0.098217964172363